Quantcast

Latest Carboplatin Stories

2014-07-08 08:29:42

CALGARY, July 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN(®) versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). The principal investigator is Tanios Bekaii-Saab, MD, associate professor and gastrointestinal oncology section...

2014-06-20 23:06:04

Italian researchers say a treatment made from a human protein can help improve the effectiveness of chemotherapy for patients fighting malignant pleural mesothelioma. Raleigh, NC (PRWEB) June 20, 2014 A team of cancer doctors says the combination of a lab-created compound based on a human protein and traditional chemotherapy drugs can help shrink mesothelioma tumors better than either treatment alone. Surviving Mesothelioma has just posted an article on the new research. Click here to...

2014-06-19 23:09:52

Study Indicates Carboplatin Can Deliver Superior Performance When Compared to Other Chemotherapy Drugs Los Angeles, CA (PRWEB) June 19, 2014 A study conducted by a surgical team at Creighton University Medical Center in Omaha, Nebraska published April 8, 2014, has shown what researchers believe is the correct chemotherapy drug to use in conjunction with surgery in patients suffering from peritoneal mesothelioma, reports the national law firm of Baron and Budd. As a result, survival rates...

2014-06-12 23:08:51

A new study suggests that platinum-based carboplatin reduces hospital stays and produces better outcomes for peritoneal mesothelioma patients than another popular drug. Raleigh, NC (PRWEB) June 12, 2014 Researchers studying the peritoneal mesothelioma treatment approach that combines cytoreductive surgery (CRS) with a wash of heated chemotherapy (HIPEC) have concluded that one drug appears to work better than another for this purpose. Click here to read the details of the article just...

2014-06-09 08:28:26

PITTSBURGH, June 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin(®) Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the initial treatment of advanced ovarian carcinoma in established combination...

2014-05-14 16:28:57

-- Difficult-to-treat squamous NSCLC patients saw clinical benefit with necitumumab plus chemotherapy regimen -- INDIANAPOLIS, May 14, 2014 /PRNewswire/ -- Lung cancer patients with metastatic squamous cell carcinoma have seen few treatment advancements over the last two decades, leaving these patients with a poor prognosis. This is in contrast to the progress seen in nonsquamous non-small cell lung cancer (NSCLC).[1] Results from the largest ever Phase III trial in first-line...

2014-04-08 08:30:08

CALGARY, April 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers (REO 018). The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin,...

2014-03-13 08:28:11

CALGARY, March 13, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2014. "In 2013, we reported data from a number of clinical studies, which included our first data correlating specific biomarkers with survival in NSCLC lung cancer patients and culminated with the reporting of our first randomized data in head and neck cancer," said...

2014-01-16 23:24:20

Researchers recommend that drug choice be guided by aspects of the patient’s condition. Raleigh, NC (PRWEB) January 16, 2014 Surviving Mesothelioma is reporting on newly published research suggesting that certain aspects of a peritoneal mesothelioma patient’s condition may have an impact on the toxicity of chemotherapy. A combination of pemetrexed (Alimta) and a platinum-based drug like cisplatin or carboplatin is the drug treatment of choice for patients with pleural mesothelioma,...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related